Pediatric ulcerative colitis: current treatment approaches including role of infliximab

Gia M Bradley, Maria Oliva-HemkerDivision of Pediatric Gastroenterology and Nutrition, Johns Hopkins University School of Medicine, Baltimore, MD, USAAbstract: Ulcerative colitis is a chronic inflammatory bowel disease that can lead to derangements in the growth, nutritional status, and psychosocial...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bradley GM, Oliva-Hemker M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/a01990c36f4f489e9e906b645fcc050e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a01990c36f4f489e9e906b645fcc050e
record_format	dspace
spelling	oai:doaj.org-article:a01990c36f4f489e9e906b645fcc050e2021-12-02T02:35:17ZPediatric ulcerative colitis: current treatment approaches including role of infliximab1177-54751177-5491https://doaj.org/article/a01990c36f4f489e9e906b645fcc050e2012-06-01T00:00:00Zhttp://www.dovepress.com/pediatric-ulcerative-colitis-current-treatment-approaches-including-ro-a10029https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Gia M Bradley, Maria Oliva-HemkerDivision of Pediatric Gastroenterology and Nutrition, Johns Hopkins University School of Medicine, Baltimore, MD, USAAbstract: Ulcerative colitis is a chronic inflammatory bowel disease that can lead to derangements in the growth, nutritional status, and psychosocial development of affected children. There are several medical options for the induction and maintenance of disease remission, but the benefits of these medications need to be carefully weighed against the risks, especially in the pediatric population. As the etiology of the disease has become increasingly understood, newer therapeutic alternatives have arisen in the form of biologic therapies, which are monoclonal antibodies targeted to a specific protein or receptor. This review will discuss the classical treatments for children with ulcerative colitis, including 5-aminosalicylates, corticosteroids, thiopurine immunomodulators, and calcineurin inhibitors, with a particular focus on the newer class of anti-tumor necrosis factor-&alpha; agents.Keywords: 5-aminosalicylates, anti-tumor necrosis factor-&alpha; agents, corticosteroids, cyclosporine, inflammatory bowel disease, thiopurine immunomodulatorsBradley GMOliva-Hemker MDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2012, Iss default, Pp 125-134 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Bradley GM Oliva-Hemker M Pediatric ulcerative colitis: current treatment approaches including role of infliximab
description	Gia M Bradley, Maria Oliva-HemkerDivision of Pediatric Gastroenterology and Nutrition, Johns Hopkins University School of Medicine, Baltimore, MD, USAAbstract: Ulcerative colitis is a chronic inflammatory bowel disease that can lead to derangements in the growth, nutritional status, and psychosocial development of affected children. There are several medical options for the induction and maintenance of disease remission, but the benefits of these medications need to be carefully weighed against the risks, especially in the pediatric population. As the etiology of the disease has become increasingly understood, newer therapeutic alternatives have arisen in the form of biologic therapies, which are monoclonal antibodies targeted to a specific protein or receptor. This review will discuss the classical treatments for children with ulcerative colitis, including 5-aminosalicylates, corticosteroids, thiopurine immunomodulators, and calcineurin inhibitors, with a particular focus on the newer class of anti-tumor necrosis factor-&alpha; agents.Keywords: 5-aminosalicylates, anti-tumor necrosis factor-&alpha; agents, corticosteroids, cyclosporine, inflammatory bowel disease, thiopurine immunomodulators
format	article
author	Bradley GM Oliva-Hemker M
author_facet	Bradley GM Oliva-Hemker M
author_sort	Bradley GM
title	Pediatric ulcerative colitis: current treatment approaches including role of infliximab
title_short	Pediatric ulcerative colitis: current treatment approaches including role of infliximab
title_full	Pediatric ulcerative colitis: current treatment approaches including role of infliximab
title_fullStr	Pediatric ulcerative colitis: current treatment approaches including role of infliximab
title_full_unstemmed	Pediatric ulcerative colitis: current treatment approaches including role of infliximab
title_sort	pediatric ulcerative colitis: current treatment approaches including role of infliximab
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/a01990c36f4f489e9e906b645fcc050e
work_keys_str_mv	AT bradleygm pediatriculcerativecolitiscurrenttreatmentapproachesincludingroleofinfliximab AT olivahemkerm pediatriculcerativecolitiscurrenttreatmentapproachesincludingroleofinfliximab
_version_	1718402366593564672

Pediatric ulcerative colitis: current treatment approaches including role of infliximab

Ejemplares similares